Selenium and prevention of prostate cancer in high-risk men: The Negative Biopsy Study

Anti-Cancer Drugs

Volumn 14, Issue 8, 2003, Pages 589-594

  Stratton, M S ^a   Reid, M E ^b   Schwartzberg, G ^a   Minter, F E ^a   Monroe, B K ^a   Alberts, D S ^a   Marshall, J R ^b   Ahmann, F R ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Negative Biopsy Study; Prostate cancer; Selenium

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CHROMOGRANIN; CHROMOGRANIN A; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SELENIZED YEAST; TUMOR MARKER; UNCLASSIFIED DRUG;

AGE; AGED; BLOOD; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; BRITTLE HAIR; BRITTLE NAIL; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FOLLOW UP; GARLIC BREATH; GENDER; HAIR DISEASE; HALITOSIS; HIGH RISK POPULATION; HUMAN; MALE; MULTICENTER STUDY; NAIL DISEASE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING; SYMPTOM; TUMOR BIOPSY; YEAST;

AGED; ALKALINE PHOSPHATASE; ANTICARCINOGENIC AGENTS; CHROMOGRANIN A; CHROMOGRANINS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; TUMOR MARKERS, BIOLOGICAL; YEASTS;

EID: 0142124893     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200309000-00003     Document Type: Review

References (32)

1. Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner, B, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983; 2:130-134.
2. Salonen JT, Alfthan G, Huttunen JK, Puska P. Association between serum selenium and the risk of cancer. Am J Epidemiol 1984; 120:342-349.
3. Wattenberg LW. Potential inhibitors of colon carcinogenesis. Am J Dig Dis 1974; 19:947-953.
4. Temple NJ, Basu TK. Selenium and cabbage and colon carcinogenesis in mice. J Natl Cancer Inst 1987; 79:1131-1134.
5. Schrauzer GN, White DA, Schneider CJ. Inhibition of the genesis of spontaneous mammary tumors in C3H mice: effects of selenium and of selenium-antagonistic elements and their possible role in human breast cancer. Bioinorg Chem 1976; 6:265-270.
6. Yu SY, Chu YJ, Li WG. Selenium chemoprevention of liver cancer in animals and possible human applications. Biol Trace Element Res 1988; 15:231-241.
7. Guttenplan JB, Kosinska W, von Pressentin MM, Rosa J, El-Bayoumy K. Effects of 1,4-phenylenebis(methylene)selenocyanate (p-XSC) and vitamin E on 4-nitroquinoline-N-oxide (4-NQO)-induced mutagenesis in lacZ mouse upper aerodigestive tissue. Mutat Res 2002; 518:85-93.
8. Ziober BL, Silverman Jr SS, Kramer RH. Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med 2001; 12:499-510.
9. Poirier KA, Milner JA. Factors influencing the antitumorigenic properties of selenium in mice. J Nutr 1983; 113:2147-2154.
10. Prokopczyk B, Amin S, Desai DH, Kurtzke C, Upadhyaya P, El-Bayoumy K. Effects of 1,4-phenylenebis(methylene)selenocyanate and selenomethionine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mouse lung. Carcinogenesis 1997; 18:1855-1857.
11. Prokopczyk B, Rosa JG, Desai D, Amin S, Sohn OS, Fiala ES, et al. Chemoprevention of lung tumorigenesis induced by a mixture of benzo[a]pyrene and 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone by the organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Lett 2000; 161:35-46.
12. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs Jr GF, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11:630-639.
13. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91:608-612.
14. Thomson CD, Robinson MF. Selenium in human health and disease with emphasis on those aspects peculiar to New Zealand. Am J Clin Nutr 1980; 33:303-323.
15. Kay RG, Knight GS. Blood selenium values in an adult Auckland population group. NZ Med J 1979; 90:11-13.
16. Morote J, Lorente JA, Encabo G. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Cancer 1996; 78:2374-2378.
17. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994; 25:236-242.
18. Gadre SG, Kale KU, Hedge R, Raste AS. Comparative study of alkaline phosphatase and prostate specific antigen in prostate cancer. Indian J Med Sci 2000; 54:136-139.
19. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001; 12:S153-S157.
20. Tsao KC, Wu JT. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001; 313:21-29.
21. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167:512-515.
22. Makuch RW, Simon RM. Sample size requirements for comparing time-to-failure among k treatment groups. J Chronic Dis 1982; 35: 861-867.
23. Makuch R, Simon R. Recommendations for the analysis of the effect of treatment on the development of second malignancies. Cancer 1979; 44:250-253.
24. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
25. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003; 8:29-37.
26. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002; 62:5325-5335.
27. Early DS, Hill K, Burk R, Palmer I. Selenoprotein levels in patients with colorectal adenomas and cancer. Am J Gastroenterol 2002; 97:745-748.
28. Svetec D, Thompson IM. PSA screening - current controversy. Ann Oncol 1998; 9:1283-1288.
29. Barry MJ. PSA screening for prostate cancer: the current controversy - a viewpoint. Patient Outcomes Research Team for Prostatic Diseases. Ann Oncol 1998; 9:1279-1282.
30. de Koning HJ, Schroder FH. PSA screening for prostate cancer: the current controversy. Ann Oncol 1998; 9:1293-1296.
31. Gatling RR. Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology. South Med J 1990; 83:782-784.
32. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151:1571-1574.